Annual report
2931.TEDINET S100VI3O
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥47.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥46.5bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥44.4bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥34.4bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥13.3bn | 2020-01-01 → 2020-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥300m | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | −¥1.5bn | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥431m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.4bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.5bn | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥6.4bn | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.5bn | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥305m | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥2.1bn | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥650m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.7bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥5.0bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.5bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥233m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | −¥2.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥73.3bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥59.6bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥57.3bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥61.0bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥15.4bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥41.1bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥39.4bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥32.1bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.4bn | at 2022-12-31d | Cons. | Net assets |
| Net assets / equity | ¥20.6bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥9.4bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥20.6bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.7bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥658m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥924m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥646m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.2bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.3bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥350m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥485m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.8bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥12.1bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥162m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-4.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-22.76 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.83 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-49.07 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-16 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥232.44 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥172.57 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥167.34 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥181.35 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥100.58 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 43.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.0% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 897 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 846 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 865 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 883 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 357 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥8.9bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥9.0bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥6.5bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥2.5bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥3.3bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥2.2bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥2.2bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.6bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.3bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥3.0bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | −¥2.0bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥3.2bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥2.7bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.1bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥42.9bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥31.9bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥26.7bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥27.8bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.4bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥11.7bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥10.1bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥31.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥21.8bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥21.5bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥22.3bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.3bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.3bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥9.7bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-15.11 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.22 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.9 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-22.94 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.12 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥228.44 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥185.88 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥186.11 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥197.18 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥89.19 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.7% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 136,411,986 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 117,150,662 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,105,455 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,161,886 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 93,153,322 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 238 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 242 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 250 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 212 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 204 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 70
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥0 |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥10m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥10m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥5.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥1.7bn |
| Biofuel Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | −¥31m |
| Biofuel Businessreportable segment | employees | at 2024-12-31 | 23 pure |
| Biofuel Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥934m |
| Biofuel Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥934m |
| Biofuel Businessreportable segment | segment assets | at 2024-12-31 | ¥9.4bn |
| Biofuel Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥410m |
| Health Care Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥658m |
| Health Care Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥2.6bn |
| Health Care Businessreportable segment | employees | at 2024-12-31 | 707 pure |
| Health Care Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥44.3bn |
| Health Care Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥44.3bn |
| Health Care Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥1m |
| Health Care Businessreportable segment | segment assets | at 2024-12-31 | ¥56.1bn |
| Health Care Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥3.0bn |
| Others Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥50m |
| Others Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥25m |
| Others Businessreportable segment | employees | at 2024-12-31 | 97 pure |
| Others Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥2.3bn |
| Others Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥2.3bn |
| Others Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Others Businessreportable segment | segment assets | at 2024-12-31 | ¥2.8bn |
| Others Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥586m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥709m |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥2.6bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥47.6bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥47.6bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥10m |
| —segment total | segment assets | at 2024-12-31 | ¥68.3bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥2.0bn |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥84m |
| Reconciling Itemsreconciling | depreciation | 2023-01-01 → 2023-12-31 | ¥4m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥2m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥1.6bn |
| Biofuel Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥48m |
| Biofuel Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | −¥133m |
| Biofuel Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥2.9bn |
| Biofuel Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥2.9bn |
| Biofuel Businessreportable segment | segment assets | at 2023-12-31 | ¥695m |
| Biofuel Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥800m |
| Health Care Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥538m |
| Health Care Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥2.2bn |
| Health Care Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥41.4bn |
| Health Care Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥41.4bn |
| Health Care Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥2m |
| Health Care Businessreportable segment | segment assets | at 2023-12-31 | ¥46.1bn |
| Health Care Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥1.5bn |
| Others Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥62m |
| Others Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥42m |
| Others Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥2.3bn |
| Others Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥2.3bn |
| Others Businessreportable segment | segment assets | at 2023-12-31 | ¥2.8bn |
| Others Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥519m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥649m |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥2.1bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥46.5bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥46.5bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥2m |
| —segment total | segment assets | at 2023-12-31 | ¥49.6bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥136m |
| Biofuel Businessreportable segment | employees | at 2024-12-31 | 23 pure |
| Health Care Businessreportable segment | employees | at 2024-12-31 | 118 pure |
| Others Businessreportable segment | employees | at 2024-12-31 | 27 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,769
| Item | Context | Value | Unit |
|---|---|---|---|
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27054-000MurakamiMiraiMember | Original text (Japanese)村上 未来 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27054-000MurakamiMiraiMember | 1977-06-19 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E27054-000MurakamiMiraiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E27054-000MurakamiMiraiMember | Original text (Japanese)(注)４ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)持分法適用の関連会社から除外したことに伴うものであります。 | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of application of equity method (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies na consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding presentation of accumulated impairment loss (text) | CurrentYearInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on liquidation receipt (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |